New hope for hard-to-treat melanoma: drug combo shows promise in early trial
NCT ID NCT04971499
First seen Feb 22, 2026 · Last updated May 21, 2026 · Updated 16 times
Summary
This study tests a combination of two drugs (dapansutrile and pembrolizumab) in people with advanced melanoma that no longer responds to standard immunotherapy. The trial has two parts: first, finding the safest dose of dapansutrile when given with pembrolizumab, and second, checking how well the combination shrinks tumors. About 26 adults with stage 3 or 4 melanoma that cannot be surgically removed are taking part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Duke Cancer Center
Durham, North Carolina, 27710, United States
Conditions
Explore the condition pages connected to this study.